TRAM
ALXN

Tuscan Ridge Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Tuscan Ridge Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,900
Closed -$382K – 635
2019
Q3 		$382K Buy
3,900
+2,250
+136% +$254K 0.02% 548
2019
Q2 		$216K Buy
+1,650
New +$213K 0.02% 607

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tuscan Ridge Asset Management's ALXN Position: Q4 2019 in Review

Tuscan Ridge Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 3,900 shares — an estimated $382K sold.

Tuscan Ridge Asset Management first reported a position in ALXN in Q2 2019 and held it in 2 quarters. The position peaked at $382K in Q3 2019. 667 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Tuscan Ridge Asset Management reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Tuscan Ridge Asset Management sold 3,900 Alexion Pharmaceuticals shares in Q4 2019, an estimated $382K.
  • Tuscan Ridge Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Tuscan Ridge Asset Management's Alexion Pharmaceuticals position peaked at $382K in Q3 2019.
  • 667 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Tuscan Ridge Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.